黄雀z
黄雀z
暂无个人介绍
IP属地:广东
54关注
21粉丝
0主题
0勋章
avatar黄雀z
08-07
$SpaceX(SPCX)$ 还要洗一把.  (仅供娱乐,不具有投资参考😂)
avatar黄雀z
08-07
$SpaceX(SPCX)$ 今晚把散户都圈进来,明天开盘就一闷棍😂
avatar黄雀z
08-05
$SpaceX(SPCX)$ 感觉还要洗一把 ,10-20%得振幅吧.
avatar黄雀z
07-13
$泡泡玛特(09992)$  超级机构懵了,还有这种好人[捂脸]  
avatar黄雀z
06-05
我也想问,华尔街那些机构都是啥吊🤣?
重仓泡泡玛特 段永平看懂了什么?
avatar黄雀z
06-04
$泡泡玛特(09992)$  超级机构要来教育阿段了😄
avatar黄雀z
04-17
$碧桂园(02007)$ 看到一毛钱这垃圾,做空!
avatar黄雀z
2025-04-16
哈哈哈看戏
avatar黄雀z
2023-03-06
Assembly Biosciences (ASMB) Gets a Buy from Mizuho Securities
avatar黄雀z
2023-03-06
Mizuho Securities analyst maintained a Buy rating on Assembly Biosciences ( – ) today and set a price target of $3.00. The company’s shares opened today at $1.53. Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to , Syed has an average return of -10.9% and a 43.14% success rate on recommended stocks. Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.75. The company has a one-year high of $2.42 and a one-year low of $0.82. Currently, Assembly Biosciences has an average volume of 321.9K. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves followin
avatar黄雀z
2022-08-30
$Assembly Biosciences Inc.(ASMB)$要往毛票走了[喷血] 
avatar黄雀z
2022-08-18
$Assembly Biosciences Inc.(ASMB)$有没有20年拿到现在的?
avatar黄雀z
2022-07-27
avatar黄雀z
2022-07-23
avatar黄雀z
2022-07-23
avatar黄雀z
2022-07-23
avatar黄雀z
2022-07-05
$德意志银行(DB)$这股票怎么连跌十来年…
avatar黄雀z
2022-06-28
avatar黄雀z
2022-06-28
avatar黄雀z
2022-05-28
$Assembly Biosciences Inc.(ASMB)$Infectious disease has definitely been on everyone’s radar for the past couple of years. And while corona made the headlines, it’s hardly the only serious pathogen out there. Hepatitis B virus (HBV) has long been known as a serious public health matter. The virus causes chronic, progressive, and severe liver disease, and while vaccines can prevent infection and transmission, there are few fully effective treatments available for patients suffering with the disease. Assembly Biosciences aims to change that situation.The company has an active research pipeline, featuring no fewer than three core inhibitor drug candidates. This is a new class of drugs, designed to interfere with the virus life cycle by blocking the virus

去老虎APP查看更多动态